The data is clinically supportive but does not change Teva's near-term financial outlook. Monitor for any future label expansion or competitive dynamics in the HD chorea market, but no immediate trading catalyst from this release.
Price Chart
Executive Summary
Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's disease chorea led to patient-reported improvements in movement and quality of life, with 74% of patients reporting improvement and over 85% reporting better daily activities and social life. The data reinforces the drug's clinical value but does not provide new financial figures, regulatory decisions, or guidance changes.
Key Facts
- Data from a real-world, decentralized study on HD chorea patients treated with AUSTEDO/AUSTEDO XR presented at the Advanced Therapeutics in Movement & Related Disorders Congress (June 4-8, 2026).
- 74% of patients reported improvement in chorea movements since initiating treatment (PGIC scale).
- Over 85% of patients reported improvements in goals related to daily activities and social life.
- 77% of caregivers reported improvements in goals related to their social life and emotional wellbeing.
- No new financial data, revenue, EPS, guidance, or regulatory action was disclosed in the press release.
Financial Impact
No financial figures provided; the press release is a clinical data update without revenue or earnings implications.
Risk Factors
- No new revenue or earnings data; the press release is purely clinical and does not alter financial expectations.
- Forward-looking statements about AUSTEDO commercialization are subject to competitive and regulatory risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307494 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.29 (+8.09%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.29 (+6.88%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.29 (+4.80%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.29 (+7.82%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.29 (+8.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.29 (+12.87%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.29 (+12.23%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.29 (+13.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access